statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	470
SG - Singapore	109
CN - Cina	68
IT - Italia	68
SE - Svezia	55
BR - Brasile	52
HK - Hong Kong	49
GB - Regno Unito	45
DE - Germania	38
VN - Vietnam	34
CI - Costa d'Avorio	30
BG - Bulgaria	25
FR - Francia	22
IN - India	13
TR - Turchia	13
RU - Federazione Russa	12
SN - Senegal	11
NG - Nigeria	9
ID - Indonesia	7
ES - Italia	6
JP - Giappone	6
CA - Canada	5
IQ - Iraq	5
FI - Finlandia	4
PL - Polonia	4
BE - Belgio	3
UA - Ucraina	3
VE - Venezuela	3
AR - Argentina	2
AT - Austria	2
EC - Ecuador	2
GR - Grecia	2
IE - Irlanda	2
JO - Giordania	2
LT - Lituania	2
NL - Olanda	2
PH - Filippine	2
PT - Portogallo	2
SK - Slovacchia (Repubblica Slovacca)	2
ZA - Sudafrica	2
AE - Emirati Arabi Uniti	1
AO - Angola	1
AU - Australia	1
AZ - Azerbaigian	1
BB - Barbados	1
BD - Bangladesh	1
CG - Congo	1
CO - Colombia	1
CR - Costa Rica	1
EE - Estonia	1
EG - Egitto	1
HR - Croazia	1
IS - Islanda	1
KE - Kenya	1
KG - Kirghizistan	1
KZ - Kazakistan	1
MX - Messico	1
PE - Perù	1
SY - Repubblica araba siriana	1
TT - Trinidad e Tobago	1
TW - Taiwan	1
UZ - Uzbekistan	1
Totale	1.215

Nome	#
Antibiotic Drugs and Unresolved Sensory Side Effects: Analysis of Eudravigilance Database of Suspected Adverse Drug Reaction Reports	142
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons	138
Listening Social Media for Pharmacovigilance Objectives: Which Usefulness?	123
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study)	121
Anticoagulant Therapy and Risk of Bleeding in Patients with Atrial Fibrillation of Four Italian Regions: The TYRION Study	118
Recommendations by the Tuscan Health Authority to Use Infliximab-Biosimilar in the Clinical Practice: Safety Impact	113
THE ECONOMIC IMPACT OF THE INTRODUCTION OF INFLIXIMAB-BIOSIMILAR: AN EMPIRICAL ANALYSIS USING THE TUSCANY HEALTHCARE ADMINISTRATIVE DATABASES	104
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease	100
The Economic Impact of the Introduction of Infliximab-Biosimilar: Preliminary Results from a Study on Rheumatologic Patients in Tuscany, Italy	98
Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments	89
Switching from infliximab-originator to infliximab-biosimilar in rheumatologic patients: The clinical impact in Tuscan Region, Italy	88
Totale	1.234

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	61	0	0	0	0	0	0	7	3	5	0	4	42
2021/2022	149	5	12	11	2	19	28	7	10	11	1	13	30
2022/2023	269	29	48	16	17	24	24	5	13	66	0	24	3
2023/2024	154	7	9	9	3	24	28	18	12	4	7	23	10
2024/2025	392	3	13	6	33	35	69	16	14	35	58	34	76
2025/2026	205	46	28	27	17	61	26	0	0	0	0	0	0
Totale													1.234

CINECA IRIS Institutional Research Information System